Actavis Acquiring Warner Chilcott For $8.5 Billion

Mani

Published onMay 20, 2013

Updated on May 13, 2021

Actavis Inc (NYSE:ACT) today announced its definitive agreement to acquire Warner Chilcott plc (NASDAQ:WCRX) in an all stock transaction valued at approximately $8.5 billion.

Actavis, Warner Chilcott Deal:

The generic drug maker Actavis Inc (NYSE:ACT) is to acquire the specialty pharmaceutical company Warner Chilcott.

The deal means that Warner Chilcott shareholders to receive 0.16 shares of Actavis for each Warner Chilcott plc (NASDAQ:WCRX) shares held. This would value Actavis shares at $20.08, a premium of 4.5 percent over Friday’s close.

Actavis shareholders would receive one share of New Actavis for each Actavis share owned by them.

Shares...

Login required to continue reading.

Setup a free account to get access to this article (no credit card required).

View Full Article

Already a member? Log in here

Mani

Mani is a Senior Financial Consultant. He has worked in Senior Management role in large banking, financial and information technology organizations. He has provided solutions for major banking and securities firms across the globe in the area of retail, corporate and investment banking. He holds MBA (Finance) and Professional Management Accounting Qualifications. His hobbies are tracking global financial developments and watching sports

Actavis Acquiring Warner Chilcott For $8.5 Billion

Actavis, Warner Chilcott Deal:

Login required to continue reading.

Get Your Business News